Does vitamin D protect against DNA damage?

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 733, Issue 1-2, 2012, Pages 50-57

  Nair Shalliker, Visalini ^a   Armstrong, Bruce K ^b   Fenech, Michael ^c  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CSIRO   (Australia)

Author keywords

Calcidiol; Calcitriol; DNA damage; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; TELOMERASE; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BONE METABOLISM; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL GROWTH; CELL SPECIFICITY; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); COLORECTAL ADENOMA; COLORECTAL CANCER; CRYPT CELL; DIET SUPPLEMENTATION; DNA DAMAGE; DNA DETERMINATION; DNA METABOLISM; DNA OXIDATION; DNA STRAND BREAKAGE; ENZYME INHIBITION; ENZYME REGULATION; GROWTH REGULATION; HUMAN; LIPID PEROXIDATION; LIVER CELL CARCINOMA; MICRONUCLEUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SKIN CELL; T CELL LYMPHOMA; TELOMERE SHORTENING; TREATMENT DURATION; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

CELL CYCLE; CELLS, CULTURED; DNA DAMAGE; HUMANS; NUTRITIONAL REQUIREMENTS; OXIDATIVE STRESS; SKIN; ULTRAVIOLET RAYS; VITAMIN D;

ANIMALIA;

EID: 84860589529     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2012.02.005     Document Type: Review

References (92)

1. Hoeijmakers J.H. DNA damage, aging, and cancer. N. Engl. J. Med. 2009, 361:1475-1485.
2. Fenech M. The genome health clinic and genome health nutrigenomics concepts: diagnosis and nutritional treatment of genome and epigenome damage on an individual basis. Mutagenesis 2005, 20:255-269.
3. van den Bergh J.P., Bours S.P., van Geel T.A., Geusens P.P. Optimal use of vitamin D when treating osteoporosis. Curr. Osteoporos. Rep. 2011, 9:36-42.
4. Ooi L.L., Zhou H., Kalak R., Zheng Y., Conigrave A.D., Seibel M.J., Dunstan C.R. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010, 70:1835-1844.
5. Ooi L.L., Zheng Y., Zhou H., Trivedi T., Conigrave A.D., Seibel M.J., Dunstan C.R. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone 2010, 47:795-803.
6. Peng X., Vaishnav A., Murillo G., Alimirah F., Torres K.E., Mehta R.G. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J. Cell Biochem. 2010, 110:1324-1333.
7. Zheng Y., Zhou H., Ooi L.L., Snir A.D., Dunstan C.R., Seibel M.J. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 2011, 71:1012-1021.
8. Holick M.F. The cutaneous photosynthesis of previtamin D3: a unique photoendocrine system. J. Invest. Dermatol. 1981, 77:51-58.
9. Holick M.F. Vitamin D: its role in cancer prevention and treatment. Prog. Biophys. Mol. Biol. 2006, 92:49-59.
10. Morris H.A. Vitamin D: a hormone for all seasons - how much is enough?. Clin. Biochem. Rev. 2005, 26:21-32.
11. Haussler M.R., Jurutka P.W., Mizwicki M., Norman A.W. Vitamin D receptor (VDR)-mediated actions of 1alpha, 25(OH)vitamin D: genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:543-559.
12. Banakar M.C., Paramasivan S.K., Chattopadhyay M.B., Datta S., Chakraborty P., Chatterjee M., Kannan K., Thygarajan E. 1alpha, 25-dihydroxyvitamin D3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J. Gastroenterol. 2004, 10:1268-1275.
13. Krishnan A.V., Trump D.L., Johnson C.S., Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. N. Am. 2010, 39:401-418.
14. Norman A.W., Mizwicki M.T., Norman D.P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 2004, 3:27-41.
15. Dixon K.M., Deo S.S., Norman A.W., Bishop J.E., Halliday G.M., Reeve V.E., Mason R.S. In vivo relevance for photoprotection by the vitamin D rapid response pathway. J. Steroid Biochem. Mol. Biol. 2007, 103:451-456.
16. Halliday G.M., Lyons J.G. Inflammatory doses of UV may not be necessary for skin carcinogenesis. Photochem. Photobiol. 2008, 84:272-283.
17. Wong G., Gupta R., Dixon K.M., Deo S.S., Choong S.M., Halliday G.M., Bishop J.E., Ishizuka S., Norman A.W., Posner G.H., Mason R.S. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway, J Steroid Biochem. Mol. Biol. 2004, 89-90(89):567-570.
18. Damian D.L., Matthews Y.J., Phan T.A., Halliday G.M. An action spectrum for ultraviolet radiation-induced immunosuppression in humans. Br. J. Dermatol. 2011, 164:657-659.
19. Tremezaygues L., Seifert M., Vogt T., Tilgen W., Reichrath J. 1,25-Dihydroxyvitamin D3 modulates effects of ionizing radiation (IR) on human keratinocytes: in vitro analysis of cell viability/proliferation, DNA-damage and -repair. J. Steroid Biochem. Mol. Biol. 2010, 121:324-327.
20. Damian D.L., Kim Y.J., Dixon K.M., Halliday G.M., Javeri A., Mason R.S. Topical calcitriol protects from UV-induced genetic damage but suppresses cutaneous immunity in humans. Exp. Dermatol. 2010, 19:e23-e30.
21. De H.P., Garmyn M., Verstuyf A., De C.P., Vandewalle M., Degreef H., Vantieghem K., Bouillon R., Segaert S. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J. Photochem. Photobiol. B 2005, 78:141-148.
22. Hager G., Formanek M., Gedlicka C., Thurnher D., Knerer B., Kornfehl J. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 2001, 121:103-109.
23. Hager G., Kornfehl J., Knerer B., Weigel G., Formanek M. Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. Acta Otolaryngol. 2004, 124:90-96.
24. Mason R.S., Sequeira V.B., Dixon K.M., Gordon-Thomson C., Pobre K., Dilley A., Mizwicki M.T., Norman A.W., Feldman D., Halliday G.M., Reeve V.E. Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J. Steroid Biochem. Mol. Biol. 2010, 121:164-168.
25. Smith S.M., Zwart S.R., Block G., Rice B.L., vis-Street J.E. The nutritional status of astronauts is altered after long-term space flight aboard the International Space Station. J. Nutr. 2005, 135:437-443.
26. Kallay E., Bareis P., Bajna E., Kriwanek S., Bonner E., Toyokuni S., Cross H.S. Vitamin D receptor activity and prevention of colonic hyperproliferation and oxidative stress. Food Chem. Toxicol. 2002, 40:1191-1196.
27. Shen Z., Zhang X., Tang J., Kasiappan R., Jinwal U., Li P., Hann S., Nicosia S.V., Wu J., Zhang X., Bai W. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells, Mol. Cell Endocrinol. 2011, 338:58-67.
28. Fedirko V., Bostick R.M., Long Q., Flanders W.D., McCullough M.L., Sidelnikov E., Daniel C.R., Rutherford R.E., Shaukat A. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev. 2010, 19:280-291.
29. Shuker D.E., Atkin W., Bingham S.A., Leuratti C., Singh R. Malondialdehyde-DNA adducts in relation to diet and disease risk--a brief overview of recent results. IARC Sci. Publ. 2002, 156:475-480.
30. Thomas P., Umegaki K., Fenech M. Nucleoplasmic bridges are a sensitive measure of chromosome rearrangement in the cytokinesis-block micronucleus assay. Mutagenesis 2003, 18:187-194.
31. Fenech M., Kirsch-Volders M., Natarajan A.T., Surralles J., Crott J.W., Parry J., Norppa H., Eastmond D.A., Tucker J.D., Thomas P. Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 2011, 26:125-132.
32. Sarkar A., Saha B.K., Basak R., Mukhopadhyay, Karmakar R., Chatterjee M. Anticlastogenic potential of 1alpha,25-dihydroxyvitamin D3 in murine lymphoma. Cancer Lett. 2000, 150:1-13.
33. Wojcik A., Bruckmann E., Obe G. Insights into the mechanisms of sister chromatid exchange formation. Cytogenet. Genome Res. 2004, 104:304-309.
34. Shanker A., Singh S.M., Sodhi A. Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunol. Med. Microbiol. 2000, 27:247-255.
35. Bull C., Fenech M. Genome-health nutrigenomics and nutrigenetics: nutritional requirements or 'nutriomes' for chromosomal stability and telomere maintenance at the individual level. Proc. Nutr. Soc. 2008, 67:146-156.
36. Kurz D.J., Decary S., Hong Y., Trivier E., Akhmedov A., Erusalimsky J.D. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J. Cell Sci. 2004, 117:2417-2426.
37. Brouilette S.W., Moore J.S., McMahon A.D., Thompson J.R., Ford I., Shepherd J., Packard C.J., Samani N.J. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369:107-114.
38. Kurosaka D., Yasuda J., Yoshida K., Yokoyama T., Ozawa Y., Obayashi Y., Kingetsu I., Saito S., Yamada A. Telomerase activity and telomere length of peripheral blood mononuclear cells in SLE patients. Lupus 2003, 12:591-599.
39. Steer S.E., Williams F.M., Kato B., Gardner J.P., Norman P.J., Hall M.A., Kimura M., Vaughan R., Aviv A., Spector T.D. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann. Rheum. Dis. 2007, 66:476-480.
40. van der H.P., van der S.G., de Boer R.A., Voors A.A., Hall A.S., Mulder M.J., van Gilst W.H., van Veldhuisen D.J. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007, 49:1459-1464.
41. Richards J.B., Valdes A.M., Gardner J.P., Paximadas D., Kimura M., Nessa A., Lu X., Surdulescu G.L., Swaminathan R., Spector T.D., Aviv A. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women. Am. J. Clin. Nutr. 2007, 86:1420-1425.
42. Jiang F., Bao J., Li P., Nicosia S.V., Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J. Biol. Chem. 2004, 279:53213-53221.
43. Zhu H., Guo D., Li K., Pedersen-White J., Stallmann-Jorgensen I.S., Huang Y., Parikh S., Liu K., Dong Y. Increased telomerase activity and vitamin D supplementation in overweight African Americans. Int. J. Obes. (Lond.) 2011, [Epub ahead of print]. 10.1038/ijo.2011.197.
44. Shen M., Cawthon R., Rothman N., Weinstein S.J., Virtamo J., Hosgood H.D., Hu W., Lim U., Albanes D., Lan Q. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of lung cancer. Lung Cancer 2011, 73:133-137.
45. Lan Q., Cawthon R., Shen M., Weinstein S.J., Virtamo J., Lim U., Hosgood H.D., Albanes D., Rothman N. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin. Cancer Res. 2009, 15:7429-7433.
46. Ciccia A., Elledge S.J. The DNA damage response: making it safe to play with knives. Mol. Cell 2010, 40:179-204.
47. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
48. Johnson C.S., Muindi J.R., Hershberger P.A., Trump D.L. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res. 2006, 26:2543-2549.
49. Mabley J.G., Wallace R., Pacher P., Murphy K., Szabo C. Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int. J. Mol. Med. 2007, 19:947-952.
50. Pacher P., Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 2007, 25:235-260.
51. Wong G., Gupta R., Dixon K.M., Deo S.S., Choong S.M., Halliday G.M., Bishop J.E., Ishizuka S., Norman A.W., Posner G.H., Mason R.S. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J. Steroid Biochem. Mol. Biol. 2004, 89-90:567-570.
52. Smith D.C., Johnson C.S., Freeman C.C., Muindi J., Wilson J.W., Trump D.L. A Phase I trial of calcitriol (1 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999, 5:1339-1345.
53. Martinesi M., Treves C., d'Albasio G., Bagnoli S., Bonanomi A.G., Stio M. Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm. Bowel Dis. 2008, 14:597-604.
54. Ceruti J.M., Scassa M.E., Flo J.M., Varone C.L., Canepa E.T. Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells. Oncogene 2005, 24:4065-4080.
55. Chen S., Law C.S., Grigsby C.L., Olsen K., Gardner D.G. A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation. J. Steroid Biochem. Mol. Biol. 2010, 122:326-332.
56. Eelen G., Verlinden L., Laureys J., Marcelis S., De C.P., Mathieu C., Bouillon R., Verstuyf A. Antiproliferative calcemic actions of trans-decalin CD-ring analogs of 1,25-dihydroxyvitamin D3. Anticancer Res. 2009, 29:3579-3584.
57. Gedlicka C., Hager G., Weissenbock M., Gedlicka W., Knerer B., Kornfehl J., Formanek M. 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J. Oral Pathol. Med. 2006, 35:472-478.
58. Geng S., Zhou S., Glowacki J. Effects of 25-hydroxyvitamin D3 on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J. Bone Miner. Res. 2010, 26:1145-1153.
59. Rohan J.N., Weigel N.L. 1Alpha 25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009, 150:2046-2054.
60. Tremezaygues L., Seifert M., Tilgen W., Reichrath J. 1,25-Dihydroxyvitamin D(3) protects human keratinocytes against UV-B-induced damage: in vitro analysis of cell viability/proliferation, DNA-damage and -repair. Dermatoendocrinology 2009, 1:239-245.
61. Flores O., Burnstein K.L. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells. Endocrinology 2010, 151:4654-4664.
62. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 2003, 278:46862-46868.
63. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 1997, 13:261-291.
64. Simmons Kovacs L.A., Orlando D.A., Haase S.B. Transcription networks and cyclin/CDKs: the yin and yang of cell cycle oscillators. Cell Cycle 2008, 7:2626-2629.
65. Echalier A., Endicott J.A., Noble M.E. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim. Biophys. Acta 2010, 1804:511-519.
66. Jensen S.S., Madsen M.W., Lukas J., Binderup L., Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery, Mol. Endocrinology 2001, 15:1370-1380.
67. Sharan C., Halder S.K., Thota C., Jaleel T., Nair S., Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil. Steril. 2011, 95:247-253.
68. Tavera-Mendoza L., Wang T.T., Lallemant B., Zhang R., Nagai Y., Bourdeau V., Ramirez-Calderon M., Desbarats J., Mader S., White J.H. Convergence of vitamin D and retinoic acid signalling at a common hormone response element. EMBO. Rep. 2006, 7:180-185.
69. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
70. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413:83-86.
71. Krimpenfort P., Ijpenberg A., Song J.Y., van V.d., Nawijn M., Zevenhoven J., Berns A. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007, 448:943-946.
72. Sharpless N.E., Bardeesy N., Lee K.H., Carrasco D., Castrillon D.H., Aguirre A.J., Wu E.A., Horner J.W., DePinho R.A. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001, 413:86-91.
73. Tavera-Mendoza L.E., Wang T.T., White J.H. p19INK4D and cell death. Cell Cycle 2006, 5:596-598.
74. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem. 1999, 68:383-424.
75. Manion M.K., Hockenbery D.M. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol. Ther. 2003, 2:S105-S114.
76. James S.Y., Mercer E., Brady M., Binderup L., Colston K.W. E.B1089a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 1998, 125:953-962.
77. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem. 2001, 12:9101-9107.
78. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
79. Lambert J.R., Eddy V.J., Young C.D., Persons K.S., Sarkar S., Kelly J.A., Genova E., Lucia M.S., Faller D.V., Ray R. A vitamin D receptor-alkylating derivative of 1alpha,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev. Res. (Phila.) 2010, 3:1596-1607.
80. Modzelewski R.A., Hershberger P.A., Johnson C.S., Trump D.L. Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumor cells in vitro MLL and human PC-3 prostate tumor cells in vitro. Proc. Am. Assoc. Cancer Res. 1999, 40:580a.
81. Artaza J.N., Sirad F., Ferrini M.G., Norris K.C. 1 25(OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J. Steroid Biochem. Mol. Biol. 2010, 119:73-83.
82. Touvier M., Chan D.S., Lau R., Aune D., Vieira R., Greenwood D.C., Kampman E., Riboli E., Hercberg S., Norat T. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1003-1016.
83. Fedirko V., Bostick R.M., Flanders W.D., Long Q., Shaukat A., Rutherford R.E., Daniel C.R., Cohen V., Dash C. Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized double-blind, placebo-controlled clinical trial. Cancer Prev. Res. (Phila.) 2009, 2:213-223.
84. V. Nair-Shalliker, Sun exposure, Vitamin and Prostate Cancer, Sun light, Vitamin D and DNA damage, Thesis, University of Sydney, 2011 (Chapter 4).
85. Bonassi S., Znaor A., Ceppi M., Lando C., Chang W.P., Holland N., Kirsch-Volders M., Zeiger E., Ban S., Barale R., Bigatti M.P., Bolognesi C., Cebulska-Wasilewska A., Fabianova E., Fucic A., Hagmar L., Joksic G., Martelli A., Migliore L., Mirkova E., Scarfi M.R., Zijno A., Norppa H., Fenech M. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 2007, 28:625-631.
86. Chang J.C., Kou S.J., Lin W.T., Liu C.S. Regulatory role of mitochondria in oxidative stress and atherosclerosis. World J. Cardiol. 2010, 2:150-159.
87. Kauppinen T.M., Suh S.W., Genain C.P., Swanson R.A. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J. Neurosci. Res. 2005, 81:190-198.
88. Mercer J.R., Cheng K.K., Figg N., Gorenne I., Mahmoudi M., Griffin J., Vidal-Puig A., Logan A., Murphy M.P., Bennett M. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ. Res. 2010, 107:1021-1031.
89. Satoh J., Nakanishi M., Koike F., Miyake S., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Kanda T., Fukazawa T., Yamamura T. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 2005, 18:537-550.
90. Henry H.L., Bouillon R., Norman A.W., Gallagher J.C., Lips P., Heaney R.P., Vieth R., Pettifor J.M., wson-Hughes B., Lamberg-Allardt C.J., Ebeling P.R. 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. J. Steroid Biochem. Mol. Biol. 2010, 121:4-6.
91. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., Durazo-Arvizu R.A., Gallagher J.C., Gallo R.L., Jones G., Kovacs C.S., Mayne S.T., Rosen C.J., Shapses S.A. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. J. Clin. Endocrinol. Metab. 2011, 96:53-58.
92. Dietary Reference Intakes for Vitamin D and Calcium, National Academies Press, US, 2011.